Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
15.64
+0.21 (1.39%)
May 5, 2025, 4:00 PM EDT - Market closed
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Mineralys Therapeutics stock have an average target of 33, with a low estimate of 24 and a high estimate of 42. The average target predicts an increase of 111.06% from the current stock price of 15.64.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Mineralys Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $42 | Strong Buy | Maintains | $30 → $42 | +168.63% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +91.88% | Mar 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 24, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $24 | Strong Buy | Maintains | $28 → $24 | +53.50% | Feb 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +91.88% | Feb 13, 2025 |
Financial Forecast
Revenue This Year
n/a
from 733.05M
Revenue Next Year
n/a
EPS This Year
-3.82
from -3.66
EPS Next Year
-3.90
from -3.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 160.3M | ||
| Avg | n/a | n/a | 79.0M | ||
| Low | n/a | n/a | 14.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.90 | -3.32 | -3.34 | ||
| Avg | -3.82 | -3.90 | -3.94 | ||
| Low | -4.33 | -4.78 | -4.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.